These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30247203)

  • 1. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Ghate S; Ionescu-Ittu R; Burne R; Ndife B; Laliberté F; Nakasato A; Duh MS
    Melanoma Res; 2019 Jun; 29(3):301-310. PubMed ID: 30247203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
    Haugh A; Daud AI
    Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
    Hadfield MJ; Sullivan RJ
    Cancer J; 2024 Mar-Apr 01; 30(2):84-91. PubMed ID: 38527261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment management for
    Haist M; Stege H; Rogall F; Tan Y; von Wasielewski I; Klespe KC; Meier F; Mohr P; Kähler KC; Weichenthal M; Hauschild A; Schadendorf D; Ugurel S; Lodde G; Zimmer L; Gutzmer R; Debus D; Schilling B; Kreuter A; Ulrich J; Meiss F; Herbst R; Forschner A; Leiter U; Pfoehler C; Kaatz M; Ziller F; Hassel JC; Tronnier M; Sachse M; Dippel E; Terheyden P; Berking C; Heppt MV; Kiecker F; Haferkamp S; Gebhardt C; Simon JC; Grabbe S; Loquai C
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy.
    Marcon IG; Valsecchi D; Durso L; Premoli E; Sangiorgi D; Perrone V; Catena L; Degli Esposti L
    Adv Ther; 2023 Sep; 40(9):3875-3895. PubMed ID: 37368101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.
    Dobry AS; Zogg CK; Hodi FS; Smith TR; Ott PA; Iorgulescu JB
    Cancer Immunol Immunother; 2018 Dec; 67(12):1833-1844. PubMed ID: 30191256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.
    Strelnikov J; Zhou A; Butt O; Ansstas M; Ansstas G
    J Natl Compr Canc Netw; 2023 Aug; 21(10):991-999. PubMed ID: 37647938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
    Falkenius J; Johansson H; Tuominen R; Frostvik Stolt M; Hansson J; Egyhazi Brage S
    BMC Cancer; 2017 Aug; 17(1):584. PubMed ID: 28851300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
    Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
    Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
    Kopecký J; Pásek M; Lakomý R; Melichar B; Mrazová I; Kubeček O; Arenbergerová M; Lemstrová R; Švancarová A; Tretera V; Hlodáková A; Žváčková K
    Cancer Med; 2024 Mar; 13(5):e6982. PubMed ID: 38491825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.
    Rigo R; Ding PQ; Batuyong E; Cheung WY; Walker J; Monzon JG; Cheng T
    Oncologist; 2024 Jan; 29(1):57-66. PubMed ID: 37648247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma.
    Bennett C; Morgan S; Aboud K; Frazer RD
    BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37348922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal strategy in managing advanced melanoma.
    Uchi H
    J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma.
    Kennedy LB; Salama AKS
    Curr Oncol Rep; 2024 Aug; 26(8):915-923. PubMed ID: 38837107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to Treatment.
    Bravo-Garzón MA; Bornstein-Quevedo L; Camargo VP; Sanku G; Jansen AM; Macedo MP; Rico-Restrepo M; Chacón M
    Cancer Control; 2024; 31():10732748241251572. PubMed ID: 38751033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
    Mooradian MJ; Sullivan RJ
    Cancer; 2023 Jul; 129(14):2117-2121. PubMed ID: 37345669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of immune markers and BRAF status in melanoma patients: Implications for prognosis.
    Kodali N; Alomary S; Lin M; Sikder S; Bhattaru A; Desai SD; Lipner SR
    Exp Dermatol; 2024 May; 33(5):e15105. PubMed ID: 38794818
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
    Lodde GC; Hassel J; Wulfken LM; Meier F; Mohr P; Kähler K; Hauschild A; Schilling B; Loquai C; Berking C; Hüning S; Eckardt J; Gutzmer R; Reinhardt L; Glutsch V; Nikfarjam U; Erdmann M; Beckmann CL; Stang A; Kowall B; Galetzka W; Roesch A; Ugurel S; Zimmer L; Schadendorf D; Forschner A; Livingstone E
    Eur J Cancer; 2023 Sep; 191():112957. PubMed ID: 37487400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of resistance and response to melanoma therapy.
    Robertson BM; Fane ME; Weeraratna AT; Rebecca VW
    Nat Cancer; 2024 Jul; 5(7):964-982. PubMed ID: 39020103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive biomarkers in melanoma.
    Maher NG; Vergara IA; Long GV; Scolyer RA
    Pathology; 2024 Mar; 56(2):259-273. PubMed ID: 38245478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.